39888-51-2

Basic information

• Product Name: AZEPAN-4-OL
• Synonyms: 1H-AZEPIN-4-OL, HEXAHYDRO-;AZEPAN-4-OL;HEXAHYDRO-1H-AZEPIN-4-OL;Azepan-4-Ol Hcl
• CAS NO: 39888-51-2
• Molecular Formula: C₆H₁₃NO
• Molecular Weight: 115.17
• Product Categories: pharmacetical
• Mol File: 39888-51-2.mol

Chemical Properties

• Boiling Point: 203.7 °C at 760 mmHg
• Flash Point: 97.4 °C
• Appearance: /
• Density: 0.983 g/cm³
• Vapor Pressure: 0.0661mmHg at 25°C
• Refractive Index: 1.468
• PKA: 15.12±0.20(Predicted)
• CAS DataBase Reference: AZEPAN-4-OL(CAS DataBase Reference)
• NIST Chemistry Reference: AZEPAN-4-OL(39888-51-2)
• EPA Substance Registry System: AZEPAN-4-OL(39888-51-2)

Safety Data

• Hazard Codes: Xi
• Statements: 37/38-41
• Safety Statements: 26-39
• Hazardous Substances Data: 39888-51-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
AZEPAN-4-OL is used as a chemical intermediate for the synthesis of various drugs and pharmaceutical ingredients. Its unique structure allows it to be a key component in the creation of new therapeutic agents.
Used in the Development of Therapeutic Agents:
In the field of medicine, AZEPAN-4-OL is used as a precursor in the development of new treatments, especially those targeting central nervous system disorders and psychiatric conditions. Its specific molecular configuration makes it a promising candidate for such applications.
Used in Organic Synthesis:
AZEPAN-4-OL also serves as a building block in organic synthesis, where it contributes to the formation of other complex chemical compounds, expanding its utility beyond direct pharmaceutical applications.
Used as a Research Target:
Due to its unique structure and properties, AZEPAN-4-OL is an important target for research and development in medicinal chemistry, where ongoing studies aim to uncover further applications and optimize its use in various chemical and pharmaceutical processes.

InChI:InChI=1/C6H13NO/c8-6-2-1-4-7-5-3-6/h6-8H,1-5H2

Upstream product

• 109162-29-0 1-benzyl-4-hydroxyhexahydro-1H-azepine 
• 61995-20-8 N-(benzyloxycarbonyl)-3-piperidone 
• 83621-33-4 benzyl 4-oxoazepane-1-carboxylate 
• 648418-25-1 benzyl 4-hydroxyazepane-1-carboxylate 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 105416-56-6 1-aza-5-oxocycloheptane 

Downstream Products

• 478832-21-2 4-hydroxy-hexahydro-1H-azepine-1-carboxylic acid 1,1-dimethylethyl ester 
• 1035922-73-6 6-(azepan-4-yloxy)-2-(4-methoxybenzyl)-7-methyl-2H-isoquinolin-1-one 
• 1374858-30-6 C₂₄H₃₀N₄O₃S 
• 1374859-11-6 C₁₄H₁₉NO₃ 

Relevant articles and documents

AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS

Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS

Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

NEW PYRIDONE DERIVATIVES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS

The present invention relates to compounds of general formula (I) wherein the groups and radicals B, k, L, U,V, W, X, Y, Z, R1, R2, have the meanings given in claim 1. Moreover the invention relates to pharmaceutical compositions containing at least one compound according to the invention. By virtue of their MCH- receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.

BENZAMIDE DERIVATIVES

A compound represented by formula (1): wherein X is a single bond or a substituted or unsubstituted lower alkylene group; Z is a saturated or unsaturated monocyclic hydrocarbon ring group or the like; and each of R1, R2, R3 and R4, which may be the same or different, is a hydrogen atom, a halogen atom, a nitro group, a cyano group, a carboxyl group, a substituted or unsubstituted alkyl group, or the like, a prodrug of said compound, or a pharmaceutically acceptable salt of said compound or prodrug has inhibitory effect on Rho kinase and hence is useful for treating diseases which are such that morbidity due to them is expected to be improved by inhibition of Rho kinase and secondary effects such as inhibition of the Na+/H+ exchange transport system caused by the Rho kinase inhibition, for example, hypertension.